Akaza Research and Conecta Join Forces for OpenClinica in Italy
OpenClinica, an open source EDC system, to hit the Italian market thanks to a new partnership.
Cambridge, MA-June 12th, 2008-Conecta, an Italian open source consulting company, and Akaza Research, developers of OpenClinica, the leading open source Electronic Data Capture (EDC) software, jointly announce a development partnership aimed at bringing OpenClinica and OpenClinica Enterprise to the Italian clinical research market.
"OpenClinica is the most advanced open source EDC system in the market today", said Carlo Daffara, research director at Conecta. "After extensive evaluation, we found the tool to be flexible, complete, and well developed according to best practices in the clinical research software market. The flexibility of open source and the validated approach help in bringing EDC to new markets that have been until now, locked into proprietary and inflexible solutions."
”We are pleased to be working with Conecta,” said Benjamin Baumann, director of business development at Akaza Research. “This partnership will further strengthen OpenClinica’s presence across Europe, allowing more researchers to benefit from a professionally supported open source solution.”
OpenClinica is already in trial use at the Disability Italian Network and the Tuscany Region, in a specialized study based on the WHO ICF protocol, and is being implemented for the Regional Health Care Authority of the Friuli-Venezia Giulia region. An early outcome is the development of an Italian localization of OpenClinica that is expected to be included in the next production release of the product. In addition, the groups will share code and best practices for the dynamic forms and complex validation functionalities.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
